Literature DB >> 23499777

Overexpression of peroxiredoxin 2 in pterygium. A proteomic approach.

V M Bautista-de Lucio1, N L López-Espinosa, A Robles-Contreras, H J Pérez-Cano, H Mejía-López, G Mendoza, M C Jiménez-Martínez, Y Garfias.   

Abstract

Pterygium is one of the most frequent pathologies in ophthalmology, and is a benign, fibrovascular lesion originating from the bulbar conjunctiva. It is composed of an epithelium and highly vascular, subepithelial, loose connective tissue. The etiology of pterygium is not clearly understood; the most widely recognized originating factor is ultraviolet radiation. It has been proposed that pterygium and neoplasia have common features, raising the possibility that pterygium is a neoplastic-like growth disorder. In this study, proteomic analysis was performed to show that peroxiredoxin 2 is overexpressed in pterygia compared to healthy conjunctivas. Twelve pterygium specimens were obtained together with healthy conjunctival tissue from the same eyes. Total proteins of pterygia and healthy conjunctivas were analyzed in SDS-PAGE. This analysis showed protein bands expressed exclusively in pterygium samples at the range of 20-25 kDa. After this, 2D electrophoresis was performed for the separation of total proteins; differential spots expressed in pterygium were excised and sequenced. Mass spectrometry (MS) data were searched in the NCBInr and EST databases using the MASCOT program. The spot was identified as peroxiredoxin 2. Real-time PCR, western blot and immunohistochemistry showed that peroxiredoxin 2 was increased in pterygium compared to healthy conjunctiva. Although, these results suggest that overexpression of peroxiredoxin 2 in pterygium could protect the cell against oxidative stress-induced apoptosis, further studies are required to establish the functional role of peroxiredoxin 2 in pterygium to determine its role in peroxidation and apoptosis in this pathology.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23499777     DOI: 10.1016/j.exer.2013.03.001

Source DB:  PubMed          Journal:  Exp Eye Res        ISSN: 0014-4835            Impact factor:   3.467


  6 in total

1.  Triple subconjunctival bevacizumab injection for early corneal recurrent pterygium: one-year follow-up.

Authors:  Angel Nava-Castañeda; Isabel Ulloa-Orozco; Lilia Garnica-Hayashi; Joaquín Hernandez-Orgaz; Maria Carmen Jimenez-Martinez; Yonathan Garfias
Journal:  J Ocul Pharmacol Ther       Date:  2014-11-04       Impact factor: 2.671

2.  Amniotic membrane conditioned medium (AMCM) reduces inflammatory response on human limbal myofibroblast, and the potential role of lumican.

Authors:  Alfredo Domínguez-López; Fátima Sofía Magaña-Guerrero; Beatriz Buentello-Volante; Luis Antonio Bautista-Hernández; Juan Pablo Reyes-Grajeda; Víctor Manuel Bautista-de Lucio; Yonathan Garfias
Journal:  Mol Vis       Date:  2021-06-15       Impact factor: 2.367

3.  Shotgun Proteomics for the Identification and Profiling of the Tear Proteome of Keratoconus Patients.

Authors:  Maite López-López; Uxía Regueiro; Susana Belén Bravo; María Del Pilar Chantada-Vázquez; Carmen Pena; Elío Díez-Feijoo; Pablo Hervella; Isabel Lema
Journal:  Invest Ophthalmol Vis Sci       Date:  2022-05-02       Impact factor: 4.925

4.  Evaluation of global differential gene and protein expression in primary Pterygium: S100A8 and S100A9 as possible drivers of a signaling network.

Authors:  Aihua Hou; Wanwen Lan; Kai Pong Law; Ser Chin Jasmine Khoo; Min Qi Tin; Yoon Pin Lim; Louis Tong
Journal:  PLoS One       Date:  2014-05-13       Impact factor: 3.240

5.  Proteomic analysis in pterygium; upregulated protein expression of ALDH3A1, PDIA3, and PRDX2.

Authors:  Sun Woong Kim; Jonghoon Lee; Boram Lee; Taiyoun Rhim
Journal:  Mol Vis       Date:  2014-08-27       Impact factor: 2.367

6.  Pyroptosis in pterygium pathogenesis.

Authors:  Naiyu Sun; Hong Zhang
Journal:  Biosci Rep       Date:  2018-05-22       Impact factor: 3.840

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.